A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma

Trial Profile

A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Aug 2017

At a glance

  • Drugs Cridanimod (Primary)
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Sponsors Xenetic Biosciences
  • Most Recent Events

    • 15 Aug 2017 According to a Xenetic Biosciences media release, interim data from this study are expected before the end of 2018.
    • 26 Jun 2017 According to a Xenetic Biosciences media release, patient dosing is expected to commence in third quarter of 2017.
    • 14 Jun 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top